0.0135  -0.007 (-33.5%)		01-08 15:58
Open: 0.0177 High: 0.0212 Volume: 6,462,682		Pre. Close: 0.0203 Low: 0.0116 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Athersys, Inc. operates as a biotechnology enterprise specializing in the research and development of regenerative medicine. Its clinical initiatives are directed towards addressing a range of health issues, including neurological disorders, cardiovascular diseases, inflammatory and immune system conditions, and pulmonary ailments. The company's primary therapeutic asset is MultiStem, an allogeneic stem cell treatment, which is currently in Phase III clinical trials. MultiStem is being evaluated for its efficacy in treating neurological damage subsequent to an ischemic stroke, acute respiratory distress syndrome, trauma-related complications, and in providing support for hematopoietic stem cell transplants, among other applications. Furthermore, Athersys is advancing MultiStem for veterinary purposes, aiming to foster tissue regeneration and recovery in animals afflicted with severe, unmet medical needs. The firm maintains key partnerships, including a collaboration with Healios K.K. to develop and commercialize MultiStem for ischemic stroke, ARDS, ophthalmic conditions, and diseases affecting the liver, kidneys, pancreas, and intestines. It also partners with the University of Minnesota to further develop the MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and its headquarters are located in Cleveland, Ohio.

Tue, 24 Oct 2023
Athersys shares suspended by Nasdaq, now trading over the counter - Cleveland.com

Tue, 17 Oct 2023
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks - InvestorPlace

Thu, 20 Apr 2023
Athersys, Inc. (NASDAQ:ATHX) Sees Significant Increase in Short Interest - 富途牛牛

Fri, 21 Jan 2022
Athersys Inc. names its new CEO - Crain's Cleveland Business

Thu, 05 Aug 2021
Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership - Business Wire

Thu, 19 Mar 2020
Athersys Inc. adds Maia Hansen as senior vice president, operations and supply chain - Crain's Cleveland Business

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date